Committees

Published: 5 April 2018
Revised 20 April 2018

Comments on agenda items for the 60th meeting of the Medicines Classification Committee to be held on 26 April 2018

The Medicines Classification Committee and the Secretary wishes to thank everyone for their valuable input and feedback on all agenda items.

A total of eight submissions commenting on agenda items for the 60th meeting were received (PDF, 11224 KB, 124 pages). Some submissions comment on more than one agenda item.

The submission on the reclassification of influenza vaccine to include registered nurses (agenda item 5.1.1) has been withdrawn by the submitter on 23 March 2018. This submission will not  be considered by the Medicines Classification Committee at the 60th meeting on 26 April 2018. Three comments were received about this proposal and these have been published at the submitters’ request. Comments received generally supported the principle of improving access to influenza vaccination.

Two comments were received about the Medsafe investigative paper on trimethoprim following reclassification (agenda item 5.3).

One comment was received about the Medsafe information paper on the manufacturers’ original pack (agenda item 5.4).

One comment was received in support of the proposed classification of phenibut and rilmazofone as prescription medicines (agenda items 5.5 and 5.6).

Three comments were received about the proposed reclassification of clotrimazole and hydrocortisone from restricted medicine to pharmacy-only medicine (agenda item 6.1). The three comments received did not support the proposal.

Three comments were received about the proposed reclassification of loratadine from pharmacy-only medicine to general sale medicine (agenda item 6.2). One comment supported the proposal. Two comments did not support the proposal.

Three comments were received about the proposed amendment to the 'prescription except when' classification for influenza vaccine (agenda item 6.3). All comments received supported the proposal.

Five comments were received about the proposed reclassification of melatonin from prescription medicine (agenda item 6.4).

Five comments were received about the proposed reclassification of modified-release paracetamol from pharmacy-only medicine to restricted medicine (agenda item 6.5). Two comments supported the proposal. Three comments did not support the proposal.

Two comments were received about the proposed amendment to the restricted classification for sedating antihistamines. Both comments supported the proposal.